Homepage News Archives - Ractigen Therapeutics

Homepage News News Highlight RAG-17

Ractigen Announces Positive Clinical Data for RAG-17 in ALS-SOD1 Treatment from Investigator-Initiated Trial

NANTONG and SUZHOU, China, Sep.10, 2024 — Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to…

ractigenSeptember 10, 2024

Company News Homepage News

Ractigen Therapeutics closes an additional $30 million in Series A+ funding to push development of its RNAa platform

Ractigen Therapeutics today announced the closing of a Series A+ financing round totaling $30 million…

EnvisionJanuary 27, 2022

Company News Homepage News

Ractigen Therapeutics closes on $17 Million Series A to advance lead program into clinical phase, led by Hillhouse Venture Capital

Ractigen Therapeutics, a leading company in the saRNA drug space, announced that it has closed…

EnvisionFebruary 10, 2021

Company News Homepage News

CB Insights lists Ractigen as one of the Top RNA biotech companies in China

Today, CB Insights China published, for the first time, a top list of RNA biotech…

EnvisionMay 19, 2020

© 2024 Ractigen Therapeutics. All Rights Reserved. Privacy Policy Terms